Harvard Bioscience, Inc. (NASDAQ:HBIO)

a global developer manfacture & marketer broad range of tools has acquired AHN Biotechologir GMBH this is expected to add $2.5 m in annual revenue

I like the prospects in regenerative medicine.

consistent growth over the last few years. Should do well long term

Have you heard about building replacement human organs? Check this out on NOVA. http://www.pbs.org/wgbh/nova/body/bhatia-biomedicine.html
Harvard Bio is the company that makes the equipment for this procedure.

Vanamonde

Growing industry, great financials and one of the top companies in its business. Tough not to pick this one.

Harvard Bioscience's Bioreactor Grows a Synthetic Tissue-Engineered Trachea Used in World's First Successful Human Transplantation

This is huge news, the stuff of Science Fiction! This stock is golden if they can continue to offer more engineered organs.

This one kept on coming up on a lot of screens. It also has some nice Lynch characteristics: small, relatively underfollowed, profitable with growing earnings, small P/E.

Addition to Russell 3000 is probably a good thing for this one, too.

On bleeding edge with bio-reactor used to replicate a human's organ(s). Successfully used in bladder & partial lung...working on heart. Bought back $10M of own stock. Do not want to be a pharmaceutical company...want to provide underlying technology. Added to Russell 3000 Index today. Look for good long term growth.

I just do. I have an extremely bearish view of it.

Debt/equity of 0.20, price/earnings of 9.00, market cap of 166.07 million, Return on Invested Capital (TTM) of 19.32, based in Massachusetts, United States, develops scientific instruments used in biotech companies.

Rock solid fundamentals. Great industry with bright growth prospects in healthcare.

Great margin of safety. Not covered by analysts. All in all a solid growth pick on sale.

Very well-run company, with great management, and an excellent track record of success. ROI is at 18% and ROE is at 23%, according to Finviz. Not "cheap" per se, but about fairly valued right now.

I can't claim to know much about this industry, but my green thumb for this one is a bet of management continuing to earn above-market returns on their investments.

Harvard Bioscience offers services that are integral to the functioning of the myriad of bio-pharm companies.

I am currently advocating a holding pattern on most bio-pharm and health care stocks (although I own MRK, ZLCS, and ATHX in real life), but this stock is intriguing.

Attractively priced, and appearing to hit a bottom. Upside in both the near future, and based upon the business, upside in the long run.

The stock is attractive for purchase now.

Bioscience looks good 26% revenue growth.

Technicals

I like this stock and so does reuters. compared to other stocks in this field it compares very well. roe is 25.6 which eclipses the competitors. price per sales is a low low 1.1. price per cash flow is 4.8 this compares to four top competitors, two of which lost money and the other two that had ratios of 10+. its debt to equity is only .2. I would like no debt but .2 is acceptable and much better than its peers. price per tangible book is 3.6. i prefer closer to 2 but still this is better than peers by far.

I also look at equity divided by share to see if share value is growing. and this company is growing share value. particularly this most recent year. it had losses 3 of 5 past years but profits each of the last two and the direction of profitability is up.

also the ceo just bought almost a million dollars of the stock for 3.54. so that is my base. I believe the stock has been hurt by these uncertain times but should recover nicely when optimism returns as its obligations of debt do not enganger it. must be patient though. but I think over the long run this one will do well.

Strong with PEG

Microscopic P/E (5.5) and impressive liquidity ratios (quick ratio of 3.1 and current ratio of 4.6) make Harvard Biosciences (HBIO) a solid buy. Throw in 26% revenue growth for the third quarter of 2010 over the third quarter of 2009 and the fact that HBIO just finished buying back about 2 million shares as part of its $10 million dollar stock repurchase program, and it becomes apparent that HBIO is poised for continued growth. And possibly the best news about HBIO is that it carries no debt, with a debt/equity ratio of .15.